Patients most often receive induction immunosuppression at the time of surgery and continue to receive maintenance immunosuppression thereafter. The main purpose of using induction agents in the early transplant period is to provide intense levels of immunosuppression to prevent the high risk of rejection in the early postoperative phase and to delay the initiation of nephrotoxic maintenance agents, as many patients are recovering from perfusion injury to their kidneys related to surgery. Following induction, maintenance agents are used to further suppress the immune system long term. The total level of immunosuppression required varies significantly on the basis of (1) type of organ, (2) age of patient, (3) time from transplant, (4) any current infection, and (5) patient response to medications, including adverse effects. In addition, every transplant center has a protocol for type and total level of immunosuppression used.
Background on the Immune System
To understand how these immunosuppressive agents are used, clinicians must have a basic understanding of the immune system. The immune system is made of 2 main subsystems, the innate system and the adaptive system. The innate system provides a rapid, nonspecific response to foreign invaders, such as bacteria Although a nonspecific marker, CD3 counts are an estimate of the number of circulating, activated T cells. When clinicians base dosing on CD3 counts, patients receive doses of rATG to maintain the CD3 count between 20 and 30 mg/ mL for 3 to 10 consecutive days; normal CD3 counts are greater than 1000 mg/mL; therefore, this strategy ensures elimination of almost all circulating T cells. 8 , 9 When dosing is based on WBC and platelet counts, patients receive 1.5 mg/kg of rATG daily for 3 to 10 days, unless WBC or platelet counts decrease. If WBC levels drop to less than 3000/ µ L or platelet levels drop to less than 75 000/ µ L, only 0.75 mg/kg is given; when WBC count is less than 2000/ µ L or platelet count is less than 50 000/ µ L, the dose is held until counts recover. Antithymocyte globulin should be infused through a central catheter with a 0.22-µ m filter over 4 to 6 hours, with close monitoring and rate titration based on hypotension, chills, and fever. 7 
Monoclonal Antibodies
Basiliximab (Simulect; Novartis, East Hanover, New Jersey), an FDA-approved drug for use in transplant recipients, is a chimeric monocloncal antibody that blocks activation of T cells.
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Because this agent is nondepleting, cytokine release syndrome is rarely a concern. Most patients do not experience adverse effects with basiliximab, although injection site pain, nausea, and vomiting may occur. Dosing of basiliximab is a simple 20 mg on postoperative days 0 and 4, infused via a peripheral or central catheter over 20 to 30 minutes. Although a bolus push can be given, it is not recommended because of increases in nausea, vomiting, and injection site pain.
Alemtuzumab (Campath, Genzyme, Cambridge, Massachusetts) is a humanized monoclonal antibody that blocks activation of T cells and B cells. 11 Cytokine release syndrome is an adverse effect with alemtuzumab, and premedications are required to minimize the risk of infusion-related reactions. Alemtuzumab can cause severe and prolonged leukopenia, neutropenia, and thrombocytopenia, because it affects multiple parts of the immune system. Although alemtuzumab is approved by the FDA only for use in the treatment of refractory B-cell chronic lymphocytic leukemia, many transplant centers have reported its successful use as induction therapy in solid organ transplantation. Given and viruses. The adaptive immune system provides a slower but more specific immune response. The adaptive immune system consists of B cells, T cells, and antibodies. This review focuses largely on T cells, as all firstline immunosuppressive agents primarily target T cells.
Achieving desirable levels of immunosuppression (prevention of rejection) must be balanced by the consequences of immunosuppression (risk of infections and cancer). Furthermore, each drug has a wide array of adverse effects that must be considered with use. This article reviews the use, dosing, and adverse effects of immunosuppressive agents that are pertinent in critical care settings.
Induction Agents

Polyclonal Agents
Antithymocyte globulin (rATG) (Thymoglobulin; Genzyme, Cambridge, Massachusetts), a drug approved by the Food and Drug Administration (FDA) for use in transplant recipients, is a polyclonal drug that depletes (causes lysis of) T cells. 7 Given that T cells are actively lysed, cytokine release syndrome is common during infusion. Cytokine release syndrome presents as fever, chills, itching, and hypotension, necessitating the use of medications before the infusion and dose titration with frequent vital-sign monitoring during the infusion. Although premedication regimens may vary, the most common regimen consists of an antipyretic agent (acetaminophen), an antihistamine (diphenhydramine), and a steroid (hydrocortisone or methylprednisolone). Other immediate adverse effects of this polyclonal medication include thrombocytopenia and leukopenia, as white blood cells (WBCs) and platelets are also lysed by rATG.
Antithymocyte globulin is usually dosed at 1.5 mg/kg for 3 to 6 doses over a 3-to 10-day period. 6 , 7 Two common dosing strategies are the off-label use of alemtuzumab, dosing is not standardized, although most often it is given as a 1-time dose of 30 mg on the day of transplant. Alemtuzumab is administered through peripheral or central access as an infusion over 2 hours.
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Steroids
High-dose intravenous (IV) steroids are almost always a part of induction regimens. Steroids have the ability to work in various parts of the immune system, but they largely block activation of T cells. 12 Methylprednisolone at a dose of 500 mg to 1500 mg is given perioperatively, followed by daily tapering doses. During these high-dose periods, patients are more likely to experience the neurotoxic effects of steroids, such as hallucinations, confusion, and insomnia. High-dose steroids can also cause acute hyperglycemia as a result of insulin resistance and hypertension as a result of adrenocortical stimulation. 12 As corticosteroids are a mainstay of maintenance immunosuppression as well, other adverse effects are discussed in detail later.
Maintenance Agents
In addition to induction agents, maintenance immunosuppressive medications are started promptly following surgery and continued throughout life. Transplant centers establish a typical 2-to 3-drug regimen that inhibits T cells at various points of the activation pathway. Most commonly, a calcineurin inhibitor (CNI), antimetabolite, and corticosteroid are combined to optimize net immunosuppression. Despite immunosuppression protocols, many recipient-specific factors affect a patient's risk of rejection and necessitate augmentation of immunosuppression goals (see Table 1 ). Although more recent regimens, such as addition or substitution with a mammalian target of rapamycin inhibitor (sirolimus and everolimus) have been proposed, their utility is extremely limited in the early postoperative period because of toxic effects, and therefore, these regimens fall outside the scope of this article. 1 , 3 , 6 Calcineurin Inhibitors Tacrolimus Tacrolimus (Prograf; Astellas, Northbrook, Illinois), a CNI, is one of the most commonly used immunosuppressive medications. Tacrolimus blocks T-cell activation. 13 The typical starting dose for patients undergoing transplant is oral tacrolimus at 0.1 mg/kg per day in 2 divided doses. Frequently, patients are administered non-weight-based doses ranging from 1 to 3 mg every 12 hours and titrated to a target drug level ranging from 8 to 12 ng/mL. Therapeutic drug monitoring in the form of trough concentration levels is required for tacrolimus to minimize risk of organ rejection while avoiding dose-dependent adverse effects such as tremors, seizures, confusion, and acute kidney injury. 6 , 13 Many adverse effects will occur independent of drug levels, such as hypertension, hyperglycemia, anxiety, hyperkalemia, hypomagnesemia, insomnia, chronic nephrotoxic effects, and infections.
If a patient is unable to take oral medications, tacrolimus can be administrated in an IV, enteral liquid, or sublingual (SL) form. The IV formulation of tacrolimus is recommended to use only when oral administration is not possible because it has a higher risk of nephrotoxic effects as a result of the IV diluent.
14 When changing from oral to IV therapy, clinicians should reduce the total daily dose of tacrolimus to roughly 33%, administered as a continuous infusion. 13 Once patients are ready to be converted back to oral tacrolimus, the first dose should be given 8 to 12 hours after discontinuation of the IV dose. Tacrolimus can be administered enterally via nasogastric or gastric tubes with a standardized formulation of a compound liquid tacrolimus; of note, the contents of tacrolimus capsules should not be emptied directly into these tubes, as tacrolimus is absorbed into the tubing and can result in erratic systemic absorption. 15 As another option, some centers allow SL administration of tacrolimus capsule contents to avoid complications of IV tacrolimus while still administrating tacrolimus to a patient who may be intubated or unable to take enteral medications. The exact dose conversion from oral to SL tacrolimus is still unknown, as this is a non-FDA-approved route of administration and has been reported to have high interpatient variability. Some patients require a 1:1 oral to SL conversion, whereas others require a 3:1 oral to SL conversion. 16 
Cyclosporine
Cyclosporine, the first CNI to receive FDA approval in 1983, has an almost identical mechanism of action to tacrolimus; it also blocks activation of T cells. Its clinical utility has significantly decreased as a result of improved outcomes seen in clinical trials comparing tacrolimus and cyclosporine. 17 The typical starting dose in patients undergoing transplant is oral cyclosporine at 10 to 18 mg/kg per day divided in 2 doses per day. 18 The dose is titrated to a predetermined target drug level, ranging from 200 to 300 ng/mL. Cyclosporine is available in 2 formulations, and the 2 are not interchangeable. Unmodified cyclosporine (Sandimmune; Novartis) generally has poor and erratic oral absorption compared with the microemulsion, modified cyclosporine (Neoral; Novartis; or Gengraf, Abbott Laboratories, Chicago, Illinois). 18 As with tacrolimus, cyclosporine also requires therapeutic drug monitoring. The dose-dependent and dose-independent adverse effects are very similar to tacrolimus. If a patient is unable to swallow the oral capsules, cyclosporine can be administrated in an IV or oral solution form. Although IV cyclosporine is only a 6-hour infusion, compared with continuous infusion with tacrolimus, it still carries the same risk of nephrotoxic effects. Unlike tacrolimus, SL cyclosporine is not a viable option.
Calcineurin inhibitors require therapeutic drug monitoring to maintain drug levels within a narrow range to optimize efficacy and minimize toxic effects. These levels must be a trough level; therefore, the blood sample should be collected approximately 30 minutes before drug administration. When a significant increase or decrease in CNI drug levels is seen, clinicians should check that the sample was collected in the correct time frame. In critical care settings, patients often have daily drug level laboratory tests; however, based on the half-life of CNI medications, a change in dose would reflect a change in drug level after 3 to 5 doses.
Antimetabolites
Mycophenolate
Mycophenolate mofetil (CellCept; Genentech, San Francisco, California) is an antimetabolite that prevents the production of new T cells and B cells. 19 Typical dosing of mycophenolate mofetil is 1000 to 1500 mg every 12 hours. Mycophenolate mofetil cannot be cut or crushed; however, it is available as an equivalent dose in IV and oral solutions for patients who are unable to swallow tablets. The most significant adverse effects of mycophenolate mofetil are leukopenia, gastrointestinal (GI) intolerance, and teratogenicity. Gastrointestinal intolerance from mycophenolate mofetil can be severe in many patients, requiring a reduction in dose or a change in formulation to mycophenolate sodium (Myfortic; Novartis). Mycophenolate sodium is a delayed release, enteric-coated formulation designed to minimize GI adverse effects in comparison to mycophenolate mofetil. No IV or enteral liquid formulations of mycophenolate sodium are available, and the enteric-coated tablets should not be cut or crushed. The 2 formulations (mycophenolate mofetil and mycophenolate sodium) are not bioequivalent and dose conversion is not 1:1.
Azathioprine
Azathioprine (Imuran, Prometheus Laboratories, Hunt Valley, Maryland) is an antimetabolite that also prevents the production of T cells and B cells. 20 Azathioprine requires metabolism to its active form, which can be inhibited by drug interactions or by genetic polymorphisms. Patients being treated with interacting medications or with certain genetic polymorphisms are at increased risk of drug accumulation and severe leukopenia. Initial doses of azathioprine are 3 to 5 mg/kg per day given once daily. Much like its antimetabolite counterpart mycophenolate, azathioprine causes leukopenia and GI intolerance.
Steroids
Steroids often are used as part of the induction regimen and maintenance immunosuppressive regimen, and they often are first-line therapy for treatment of rejection. 12 Most commonly, oral prednisone, oral methylprednisolone, or IV methylprednisolone are used as part of the maintenance immunosuppression regimen. Given that prednisone is not available in IV formulation, conversion between oral prednisone and IV methylprednisolone is common, with a dose conversion of 5 to 4 mg, respectively. 21 Prednisone and methylprednisolone tablets can be crushed and administered through enteral tubes, or enteral liquid formulations may be available. The maintenance dose of steroids can vary significantly; doses of prednisone may be as small as 5 mg or as large as 0.5 mg/kg. Dosages for patients should be tapered to these levels after induction to minimize the complications of longterm steroid use, which include cardiovascular disease, hyperlipidemia, hyperglycemia, hypertension, cataract formation, and osteoporosis.
Drug Interactions
In addition to immunosuppressive drug therapy adjustments based on drug levels, rejection risk, infections, and adverse effects, clinicians should be cognizant of the many drug interactions these agents have. Principally, tacrolimus and cyclosporine have many interactions due to their metabolism through enzymes and transporters in the intestine and liver, cytochrome P450, and p-glycoprotein efflux pump. 22 Table 2 lists some of the more common drug-drug interactions seen in an ICU setting. The 2 most common types of interacting medications are enzyme inhibitors and enzyme inducers. Inhibitors will increase CNI levels and will typically show their drug interactions quickly, requiring a decrease in CNI drugs to be made within days. When inhibitors are subsequently discontinued, their interacting effect is also gone quickly. On the contrary, inducers will cause a delayed decrease in CNI levels, typically not seen for 1 to 2 weeks. When inducers are discontinued, their interacting effect may take weeks to abate. 22 
Conclusion
Care of patients receiving organ transplants is truly a multidisciplinary task; physicians, pharmacists, nurses, coordinators, and social/financial support are critical for successful outcomes. Having a good understanding of immunosuppression is imperative to excellent patient care. By understanding the immune system and its role in activation of T cells against the allograft, one can see the need for multiple drugs that inhibit the proliferation of T cells and other immune-activating cells through multiple pathways. The standard of care at most transplant centers is to provide some sort of induction therapy and 3 immunosuppressive drugs immediately posttransplant. In the last decade, there has been an increased push to minimize the use of steroids when possible and to use more potent immunosuppressive agents within each class. Tacrolimus has a 10-to 100-fold greater in vitro immunosuppressive activity than cyclosporine. Clinical studies have shown this increased potency to result in fewer episodes of acute rejection; however, data are less clear as to whether this benefit extends to improved graft and patient survival. We see a similar difference in potency between azathioprine and
